News – Page 483 – Endpoints News

George Yancopoulos says he's on the trail of the holy grail: ‘This could represent the next breakthrough for ...

3 years ago

After a bust with knee pain drug and 3 Covid-19 flops, Ampio lays off staff; Antibody startup nabs second deal in two ...

3 years ago

Days after an FDA approval for its psoriasis drug, Arcutis looks to raise $150M in public capital

3 years ago

Roche, Genentech place a $100M bet on fibrosis, nabbing PhII program from Kiniksa

3 years ago

Gene therapy biotech uses its manufacturing sites as collateral to net a $100M loan

3 years ago

Despite $5B sales for Keytruda, Merck hits two PhIII snags as it continues to build its multibillion-dollar drug

3 years ago

Incyte axes JAK1 inhibitor from pipeline two years after a PhIII flop crushed hopes

3 years ago

PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde

3 years ago

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

3 years ago

Alnylam heralds PhIII APOLLO-B win on way to creating an ‘industry leading TTR franchise’

3 years ago

Gilead reports 'very strong quarter' despite slipping Veklury sales

3 years ago

Right as it gets a date with FDA, Forma offloads IDH1 inhibitor to Rigel

3 years ago

Curia nets contract for cannabinoid candidate and taps a new president of manufacturing

3 years ago

'What’s wrong with having lots of patents?' Federal appeals judge sides with AbbVie in Humira case

3 years ago

A 'chilling,' 'onerous' and 'historic mistake': Pharma CEOs take their turn blasting drug pricing deal

3 years ago

3M plans to spin out $8.5B healthcare division into its own company

3 years ago

MarketingRx roundup: Biohaven study links migraine and mental health; B+L bows TikTok challenge

3 years ago

Granfluencers and boomfluencers: Is the hipster oldster social media trend moving to pharma?

3 years ago

How do you put a positive spin on ugly data? AC Immune gives it a shot in the wake of the latest crenezumab flop

3 years ago

FDA greenlights Marius' oral hypogonadism pill; VBL Therapeutics makes cuts to its workforce

3 years ago

Who's afraid of the FTC? CSL gets its regulatory ducks lined up for $11.7B M&A deal

3 years ago

Ouch: Eliem’s pain drug fails second PhII trial, gets scrapped

3 years ago

CEO of Danish immunotherapy startup hits the exit in the latest C-suite shakeup

3 years ago

After FDA requests a new trial, Allarity drops a cancer drug from solo development

3 years ago

First page Previous page 480 481 482483484 485 486 Next page Last page